We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Biomarker Research for Personalized Medicine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01488591
Recruitment Status : Unknown
Verified May 2013 by Jae-Gook Shin, Inje University.
Recruitment status was:  Recruiting
First Posted : December 8, 2011
Last Update Posted : May 31, 2013
Information provided by (Responsible Party):

Study Description
Brief Summary:

The aim of this study :

  1. Through the study of genes of protein, transporter, translator and epigenome investigating the effect of anti-cancer treatment or the key factor of the MDR (Multidrug resistance) on the blood cancer patients who are under the anti-cancer sork treatment
  2. Giving a service of anticancer medicine therapeutic drug monitoring (TDM) and genotyping

Condition or disease
Hematologic Neoplasms

Study Design

Study Type : Observational
Estimated Enrollment : 1000 participants
Time Perspective: Prospective
Official Title: Biomarker Research for Personalized Medicine in Blood Cancer Patient
Study Start Date : April 2009
Groups and Cohorts

Outcome Measures

Biospecimen Retention:   Samples With DNA
whole blood

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
healthy volunteers

Inclusion Criteria:

  • Korean
  • Clinical diagnosis of Hematologic neoplasms
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01488591

Contact: Jae Gook Shin, M.D.,Ph.D. 82-51-890-6709 phshinjg@inje.ac.kr

Korea, Republic of
Inje University Recruiting
Busan, Korea, Republic of, 614-735
Contact: Jae Gook Shin, M.D., Ph.D.    82-51-890-6709    phshinjg@inje.ac.kr   
Sponsors and Collaborators
Inje University
More Information

Responsible Party: Jae-Gook Shin, Department of Pharmacology and Pharmacogenomics Research Center, Inje University
ClinicalTrials.gov Identifier: NCT01488591     History of Changes
Other Study ID Numbers: 09-029
First Posted: December 8, 2011    Key Record Dates
Last Update Posted: May 31, 2013
Last Verified: May 2013

Additional relevant MeSH terms:
Hematologic Neoplasms
Neoplasms by Site
Hematologic Diseases